Vessell will oversee a team that is developing lutetium-177 for cancer therapies. He brings more than 25 years of experience in healthcare, manufacturing, and financial services, and he recently served as the U.S. nuclear medicine supply chain lead for GE Healthcare's Pharmaceutical Diagnostics group.